

30436.43USU1/WJW/KSC/sy

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Dale E. Yelton and Mae Joanne Rosok

Serial No. : 08/905,293

Examiner: Devi

Filed: August 1, 1997

Art Unit: 1643

Title: **A METHOD FOR INHIBITING IMMUNOGLOBULIN-INDUCED
TOXICITY RESULTING FROM THE USE OF IMMUNOGLOBULINS IN
THERAPY AND IN VIVO DIAGNOSIS**

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being transmitted by facsimile to 1-703-305-7939 at the United States Patent and Trademark Office on July 7, 1998.

By: 

Name: Sherlin Yaghoubzadeh

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

SUPPLEMENTAL PRELIMINARY AMENDMENT

Please amend the subject application as follows:

In the Claims:

23. (Amended) A pharmaceutical composition comprising a pharmaceutically effective amount of a structurally altered immunoglobulin, and an acceptable carrier, wherein the structurally altered immunoglobulin (1) recognizes and binds a target, the target is associated with cancer and (2) has an inactivated CH₂ domain.

a 24. (Amended) A pharmaceutical composition comprising a pharmaceutically effective amount of structurally altered Ig fusion protein, and an acceptable carrier, wherein the structurally altered Ig fusion protein (1) recognizes and binds a target, the target is associated with cancer and (2) has an inactivated CH₂ domain.